Neurotune launches sarcopenia test to speed up own drug development
This article was originally published in Clinica
Executive Summary
Biotech firm Neurotune has launched for research use a diagnostic for sarcopenia, a muscle loss disorder. It believes the test will help accelerate the development of its own pipeline of drugs for the disease. The test, which the firm claims is the first available for sarcopenia, could help to stratify patients, thereby allowing more targeted clinical trials. It could eventually be marketed as a companion diagnostic for use alongside these drugs, if approved.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.